Biotech Stocks Are Surging in 2026. This One Stands Out After a Pullback.BY Bret Jensen · Jul 5, 2026, 11:15 AM EDTGNNSFJNJLEGN
Covered Call ETFs: Smart Income Tool or Overpriced Compromise?BY Kate Stalter · Jul 4, 2026, 12:15 PM EDTJEPIJEPQQYLD
Going Back to the Well in a Sector That’s WorkingBY Bret Jensen · Jun 28, 2026, 11:15 AM EDTABBVINCYMU
Wendy’s Goes Full Meme: How I’m Riding the Reddit MomentumBY Stephen Guilfoyle · Jun 26, 2026, 11:45 AM EDTWEN
Options Trading: Taking a Shot on Celestica After Last Week’s HitBY Bob Lang · Jun 8, 2026, 2:45 PM EDTCLS
While Everyone Was Selling, I Initiated a New Position in This Mid-Cap BiotechBY Bret Jensen · Jun 7, 2026, 11:15 AM EDTASNDSOXSPCX
While Everyone’s Swinging for the Fences, I’ll Continue to Hit SinglesBY Bret Jensen · May 31, 2026, 11:15 AM EDTALKTBANDCRM
Down 20%, Activist Involved, Insiders Buying: I’m Going With the FlowBY Bret Jensen · May 24, 2026, 11:55 AM EDT
Citigroup and I Are Aligned on These 3 Mid-Cap Biopharma StocksBY Bret Jensen · May 22, 2026, 11:35 AM EDT
A Low-Priced Biotech Is Back in the Bargain Bin – And I’m AddingBY Bret Jensen · May 17, 2026, 10:30 AM EDT
Doug Kass: A Market Bacchanal Rages On, While I Remain CelibateBY Doug Kass · May 13, 2026, 2:30 PM EDT
I've Got My Finger on the Trigger for These Two Biopharma StocksBY Bret Jensen · May 11, 2026, 12:45 PM EDTDDOGAMDCOLL
My 2026 Stock Pick Is Up 25%. Here’s How I’m Playing It Now.BY Bret Jensen · May 10, 2026, 12:15 PM EDTAKAMCTRADVN
